Drug Type Monoclonal antibody |
Synonyms |
Target |
Mechanism LRRC32 inhibitors(Transforming growth factor beta activator LRRC32 inhibitors), TGF-β1 inhibitors(Transforming growth factor beta 1 inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Inactive Organization- |
Drug Highest PhasePhase 1 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Advanced Malignant Solid Neoplasm | Phase 1 | - | 31 Jul 2023 | |
Solid tumor | Phase 1 | US | 04 Jan 2023 |